Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE versus BENZEDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE versus BENZEDRINE.
AMPHETAMINE vs BENZEDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphetamine is a central nervous system stimulant that promotes release of monoamines (dopamine, norepinephrine, and serotonin) from presynaptic terminals and inhibits their reuptake, leading to increased synaptic concentrations. It also reversibly inhibits monoamine oxidase (MAO) and may directly stimulate postsynaptic receptors.
Benzedrine (racemic amphetamine) releases dopamine and norepinephrine from presynaptic neurons, blocks their reuptake, and inhibits monoamine oxidase, increasing synaptic monoamine levels.
5-60 mg/day orally, divided into 2-3 doses; immediate-release: initial 5 mg once or twice daily, increase by 5 mg increments weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly
Oral: 5-10 mg once or twice daily, maximum 40 mg/day. Intramuscular: 5-10 mg every 30-60 minutes as needed, maximum 40 mg/day.
None Documented
None Documented
Clinical Note
moderateAmphetamine + Torasemide
"Amphetamine may increase the hypotensive activities of Torasemide."
Clinical Note
moderateAmphetamine + Tranilast
"Amphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateHydroxyamphetamine + Tranilast
"Hydroxyamphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateDextroamphetamine + Tranilast
"Dextroamphetamine may decrease the sedative activities of Tranilast."
Terminal elimination half-life: 10-13 hours (adults) for immediate-release formulations; prolonged to 12-14 hours in chronic use. Clinical context: Half-life correlates with duration of action; twice-daily dosing may be needed.
Terminal elimination half-life: 4-6 hours in adults (range 4-8 hours). Clinically, duration of action correlates with half-life, but tolerance may develop with repeated dosing.
Primarily renal (70-80% as unchanged drug and metabolites); minor biliary/fecal (approximately 2-5%). Urinary pH-dependent: acidic pH enhances elimination, alkaline pH reduces it.
Renal (30-40% unchanged, pH-dependent), with minor biliary/fecal elimination. At acidic urine pH, elimination half-life is shortened; at alkaline pH, reabsorption increases.
Category D/X
Category C
CNS Stimulant
CNS Stimulant